Psilocybin and Anhedonia: Can It Restore Pleasure?

Psilocybin & Emotional Processing

6 months of sustained anhedonia improvement

In a 2024 follow-up of the landmark NEJM trial, psilocybin maintained significantly greater anhedonia improvement than escitalopram at 6 months. Escitalopram patients deteriorated after stopping medication.

Erritzoe et al., EClinicalMedicine (Lancet), 2024

46%

of SSRI patients report emotional blunting, including reduced positive emotions (Goodwin et al., 2017)

NEJM RCT

psilocybin outperformed escitalopram on anhedonia as a secondary outcome (N=59)

2025

Molecular Psychiatry: SSRIs blunted hedonic response to music; psilocybin preserved it

Erritzoe et al., EClinicalMedicine (Lancet), 2024

View as image ↗

When depressed patients in a clinical antidepressant trial listened to music with unexpected pleasurable moments (the kind that normally produces a small shiver of delight), something revealing happened. In the escitalopram group, the brain's pleasure response to those musical surprises was measurably blunted. In the psilocybin group, it was not.^[1] That 2025 finding, published in Molecular Psychiatry, cuts to the heart of what makes anhedonia so disabling, and why it responds so differently to different antidepressant treatments.

Anhedonia is the loss of the ability to feel pleasure. It is one of the two core diagnostic criteria for major depressive disorder. It is also the symptom where psilocybin research shows its sharpest advantage over conventional antidepressants, according to a growing body of evidence. This article covers what the research shows on psilocybin specifically for anhedonia. For the broader clinical case, see the complete guide to psilocybin for major depression.

What Anhedonia Is (and Why It Is Not Just Sadness)

Anhedonia is the inability to feel pleasure. It is not the same as sadness, and this distinction matters for treatment. Sadness hurts, but it confirms that the emotional system is working. Anhedonia is the absence of positive feeling: food stops tasting good, music sounds flat, activities that used to matter feel pointless. Many people with depression describe it as watching their life from behind glass.

For clinical purposes, anhedonia shows up as a loss of motivation and reward. Patients no longer feel pulled toward things they used to enjoy. Getting out of bed is effortful not just because they are tired but because nothing waiting on the other side feels worth getting up for. Pleasure, connection, and anticipation have all gone quiet.

Antidepressants, particularly SSRIs (drugs that increase serotonin availability in the brain), reduce depressive symptoms broadly and are effective for many patients. But a large proportion report that one thing does not return with treatment: pleasure.

A 2017 survey of 1,829 patients on SSRIs, SNRIs (a related class of antidepressants), and tricyclics found that 46% reported emotional blunting: a reduction in the full range of emotional experience, including positive emotions and the capacity for pleasure.^[2] Across individual SSRIs, the blunting prevalence ranged from 43% to 47%. Some other surveys put the rate of emotional numbing even higher.

Nearly half the patients in that survey reported that their medication dampened positive emotions alongside negative ones. SSRIs may, for a substantial minority, be trading depression's misery for a different kind of emptiness, one that clinical scales measuring sadness and suicidality may not fully capture.

Anhedonia is the clinical name for that emptiness. And it is where psilocybin research has found the most consistent divergence from conventional antidepressants.

The Head-to-Head Trial: Psilocybin vs. Escitalopram on Anhedonia

The most rigorous direct comparison is the 2021 phase 2 randomized controlled trial published in the New England Journal of Medicine.^[3] Carhart-Harris and colleagues enrolled 59 patients with moderate-to-severe major depressive disorder and assigned them to either psilocybin (two sessions at 25mg, three weeks apart, with psychological support throughout) or escitalopram (a daily SSRI for six weeks, with matching placebo sessions to maintain parity in the therapeutic context).

On the primary outcome (a standardized depression rating scale, the QIDS-SR-16, at week 6), the two treatments did not differ significantly. Psilocybin was not statistically superior to escitalopram on the headline depression score. That result has been cited in both directions: as evidence that psilocybin works (non-inferior to an SSRI at 6 weeks) and as evidence that it does not (failed to beat the gold standard).

The secondary measures tell a more differentiated story. Wellbeing, emotional acceptance, work and social functioning, and anhedonia all favored psilocybin. On the anhedonia subscale (which measures patients' restored capacity to experience pleasure), the psilocybin group showed clinically meaningful improvement over the escitalopram group. This was not a post-hoc finding; it was a prespecified secondary outcome in a double-blind trial.

The NEJM primary result is about overall depression severity. The secondary results are about what kind of recovery patients experience. Escitalopram reduced depression scores. Psilocybin reduced depression scores and restored pleasure. The difference between those two outcomes is clinically significant for patients who describe anhedonia as their primary complaint.

The Music Test: How the Two Drugs Treat Pleasure Differently

Abstract anhedonia scores on a clinical questionnaire are hard to visualize. A 2025 substudy from Molecular Psychiatry made the difference concrete.^[1]

Harding and colleagues took the same 59 patients from the NEJM trial and tested how each group responded to music. Specifically, they measured the pleasure response to musical "surprises": the unexpected chord resolutions and melodic turns that the brain processes as pleasurable when it correctly anticipates them. This is the brain's prediction-and-reward system in direct action. When music resolves an expectation in a satisfying way, the brain releases a small pleasure signal. It is how music makes people feel something.

In the escitalopram group, the response to these musical surprises was reduced. The pleasure signal associated with musical anticipation-and-resolution was blunted. Participants also scored lower on music-evoked vitality (that sense of energy and feeling alive that certain music produces).

In the psilocybin group, neither effect appeared. The pleasure response to musical surprises was maintained. Music-evoked vitality held steady.

This is behavioral evidence from a controlled trial that the two treatments diverge specifically at the point of hedonic capacity. The music finding is not a metaphor for a more complicated clinical picture. It is a direct, quantified test of anhedonia's most concrete symptom: the ability to feel pleasure when encountering something pleasurable.

How the Brain Changes: The Imaging Evidence for Why Pleasure Returns

Two lines of brain imaging data explain the behavioral differences.

The first comes from a 2018 study by Roseman and colleagues in 33 participants: 17 with treatment-resistant depression and 16 healthy controls.^[4] The researchers measured how quickly and accurately patients could identify emotions on faces, one month after psilocybin treatment. This task probes the same emotional processing systems involved in anhedonia. Depressed patients improved significantly in reaction time. Healthy controls showed no comparable change.

The most important finding was the correlation. Faster emotion face recognition after psilocybin tracked directly with lower scores on the SHAPS (Snaith-Hamilton Pleasure Scale, a validated clinical measure of anhedonia). The more a patient improved at reading emotions on faces, the more they improved at experiencing pleasure. Depression had blunted both capacities. Psilocybin appeared to restore both together.

The second line comes from Mertens and colleagues in 2020, who measured the relevant brain circuits directly in 17 patients with treatment-resistant depression.^[5] They tracked the amygdala (the brain's emotional alarm system, which processes threat and reward signals and is dampened in depression) and the connection between the amygdala and the prefrontal cortex (the region that puts emotional signals into context). After psilocybin, amygdala activity during emotional processing increased. The functional connection between the amygdala and prefrontal cortex normalized. Both changes predicted clinical improvement.

The implication is important: emotional restoration was not a side effect of getting less depressed. Getting less depressed was partly a result of the brain becoming emotionally responsive again. Psilocybin works through the emotional pathway rather than around it.

The 2025 American Journal of Psychiatry neuroimaging substudy adds the direct SSRI comparison.^[6] Wall and colleagues used fMRI (brain activity imaging) on the same NEJM cohort and found that escitalopram significantly reduced brain activation in response to all types of emotional stimuli: happy faces, fearful faces, and neutral faces alike. Psilocybin showed no such reduction. For some stimuli, psilocybin produced slight increases in emotional brain activation. The two treatments' effects on the amygdala moved in opposite directions.

This is the brain-level explanation for what Harding found behaviorally in the music study. The escitalopram group was not just reporting less pleasure. Their brains were measurably less active in response to emotional and pleasurable input across the board.

For a deeper look at what these brain imaging results show across all domains of emotional processing, see How Psilocybin Changes Emotional Responsiveness: Brain Imaging Evidence.

The Neuroplasticity Explanation: Why One Session Can Produce Months of Change

Psilocybin is active in the body for roughly 4 to 6 hours. Anhedonia improvements in clinical trials persist for months. A 2024 preclinical study in mice offers a structural explanation for how that gap works.^[7]

Zhao and colleagues found that psilocybin triggered rapid synaptogenesis (the formation of new synaptic connections between neurons) in the medial prefrontal cortex and the hippocampus. These are regions directly involved in reward processing, emotional regulation, and the encoding of emotional memories. The new connections formed quickly after a single dose and persisted after the drug had cleared the system. Antidepressant-like behavioral changes in the mice were both rapid in onset and sustained in duration.

Animal studies do not map directly onto human experience. The same mechanisms operating in mice may differ in strength, speed, or clinical relevance in human brains. But the finding provides a plausible structural explanation for a pattern that appears consistently in the human data: psilocybin produces emotional changes after a single session that remain measurable six months later. If the brain is forming new physical connections during or after the experience, connections in the reward and emotional circuits that depression had left underconnected, the durability of the effect makes mechanistic sense.

Does It Last? The Six-Month Evidence on Psilocybin Anhedonia Recovery

The most important durability data comes from a 2024 observational follow-up of the NEJM cohort, published in EClinicalMedicine (a Lancet journal).^[8] Erritzoe and colleagues followed the same 59 patients for six months after the trial concluded.

The pattern was consistent. Psilocybin patients maintained their antidepressant effects at 6 months. Escitalopram patients declined after stopping medication. At the 6-month mark, psilocybin was significantly superior on anhedonia. The pleasure-restoring effect that psilocybin produced during the controlled trial had not faded by half a year out. The anhedonia gains from escitalopram, which required ongoing daily medication to maintain, declined when the drug stopped.

This is observational follow-up data, not a controlled extension: patients were not randomized to continue or discontinue medication, and some confounding is possible. But the direction is consistent with the neuroplasticity hypothesis. SSRIs work by keeping serotonin elevated while the drug is present; the effect requires the drug to persist. Psilocybin may work by structurally remodeling how emotional circuits connect, which persists after the compound clears.

For readers interested in how this durability difference plays out across all emotional outcomes, see Can Psilocybin Reverse SSRI-Induced Emotional Numbness? and Psilocybin and Emotional Reconnection: Why Patients Report Feeling Again.

Same Clinical Improvement, Opposite Routes: A 2025 Secondary Analysis

A 2025 secondary analysis published in Translational Psychiatry found something important about how the two treatments reach their clinical endpoints.^[9]

Martens and colleagues examined the NEJM trial cohort and found that both psilocybin and escitalopram reduced negative affective bias (the tendency, characteristic of depression, to interpret ambiguous information as threatening or negative). On that clinical measure, both treatments worked. They converged on the same outcome.

But the route diverged sharply. Psilocybin maintained or increased sensory-emotional integration (the richness of the connection between sensory input and emotional response). Escitalopram reduced activation in the brain regions involved in emotional processing.

Two treatments, one clinical result, opposite emotional mechanisms. Psilocybin corrected depressive thinking by making emotional experience richer. Escitalopram corrected it partly by making emotional response quieter.

For patients whose primary complaint is not only persistent sadness but the absence of aliveness (the inability to feel music, food, connection, or anticipation), this difference in route is clinically material. Both treatments may move the depression score. They do not move it the same way.

What the Research Picture Shows

The evidence on psilocybin and anhedonia converges from multiple independent directions: a double-blind randomized controlled trial with anhedonia as a prespecified secondary outcome, a 6-month observational follow-up showing durable superiority over SSRI treatment, a behavioral substudy showing preserved hedonic response to music, a neuroimaging substudy showing no emotional brain blunting in the psilocybin group, a mechanism study showing restored amygdala function correlates with clinical improvement, and a neuroplasticity explanation for durability.

For a single clinical symptom, this degree of convergence across methods (RCT, imaging, behavior, mechanism, follow-up) is unusual in the psychedelic research literature.

Important limits apply. All results derive from phase 2 trials with small samples. The foundational NEJM cohort is 59 patients. Psilocybin is not FDA-approved for depression. Every study in this evidence base administered psilocybin in a carefully supervised clinical setting with psychological preparation before the session and integration support afterward. The treatment in these studies is not a drug alone. It is a drug in a structured therapeutic context. Results from that context cannot be assumed to replicate outside it.

Larger phase 3 trials are currently underway. The picture may become clearer or more complicated as that data comes in. The current evidence is more consistent on the anhedonia question than on most questions in this field, but it is not settled.

For the full emotional processing story, see Psilocybin and Emotional Processing: The Opposite of Blunting. For the head-to-head trial in full, see Psilocybin vs. Escitalopram: The Imperial College Head-to-Head Trial. For readers exploring non-psilocybin approaches to emotional support, see Functional Mushrooms for Depression: Non-Psychedelic Options.

The Bottom Line

Psilocybin produced significantly greater improvement in anhedonia than escitalopram in the landmark NEJM head-to-head RCT, with effects maintained at 6 months while SSRI patients declined after stopping medication. Brain imaging shows escitalopram reduces emotional brain activation across all stimulus types; psilocybin does not. The mechanism appears to involve restoration of emotional processing circuits rather than suppression of emotional signal. These results come from supervised clinical trials and cannot be assumed to replicate outside that research context.

Frequently Asked Questions

Does psilocybin help with anhedonia?

Clinical trial data says yes for some patients. In a 2021 phase 2 RCT in the New England Journal of Medicine, psilocybin outperformed escitalopram on anhedonia as a secondary outcome (N=59). A 2024 Lancet follow-up found those improvements held at 6 months while SSRI patients declined after stopping medication. All evidence comes from supervised clinical trials with structured preparation and integration support, not recreational use.

Can psilocybin restore the ability to feel pleasure?

In clinical trial populations, it measurably did. A 2025 Molecular Psychiatry study found psilocybin preserved the pleasure response to unexpected music where escitalopram blunted it. A 2018 study found that improved emotion recognition after psilocybin correlated directly with lower scores on a validated anhedonia scale. The mechanism appears to involve restoration of emotional brain circuits rather than suppression of negative signal.

Is psilocybin better than SSRIs for anhedonia?

The current evidence from one double-blind RCT and its follow-ups suggests psilocybin produced greater anhedonia improvement than escitalopram, with longer-lasting effects after medication stops. These results come from a phase 2 trial with N=59. Psilocybin is not FDA-approved for depression. Larger confirmatory trials are needed before any definitive clinical comparison can be made.

How long does psilocybin's effect on anhedonia last?

A 2024 observational follow-up of the NEJM cohort found psilocybin's anhedonia improvements held at 6 months, while patients who stopped escitalopram declined. Preclinical research shows psilocybin triggers rapid formation of new neural connections in reward-processing brain regions, which may explain the durability. Data beyond 6 months is limited in current published research.

What is anhedonia and how does psilocybin treat it?

Anhedonia is the inability to feel pleasure: food loses taste, music goes flat, activities lose meaning. It is one of the two core diagnostic criteria for major depressive disorder. Psilocybin appears to treat it by restoring emotional responsiveness. Brain imaging shows psilocybin maintains emotional brain activation in response to pleasurable and emotional stimuli, while escitalopram reduces that activation across all stimulus types, including pleasant ones.

Does escitalopram help with anhedonia?

Escitalopram reduces depression broadly, and some anhedonia improvement follows. But in head-to-head comparison with psilocybin, escitalopram showed less anhedonia improvement in the NEJM RCT and greater deterioration after stopping at 6 months. A 2025 brain imaging study found escitalopram significantly reduced brain activation to all emotional stimuli, including pleasurable ones, consistent with the 46% rate of emotional blunting self-reported by SSRI patients in large surveys.

Sources & References

1. 1. Source details for this reference are not yet available.
2. 2RTHM-00872·Goodwin, G M et al. (2017). “Emotional blunting with antidepressant treatments: A survey among depressed patients..” Journal of affective disorders.Study breakdown →PubMed →↩
3. 3. Source details for this reference are not yet available.
4. 4. Source details for this reference are not yet available.
5. 5. Source details for this reference are not yet available.
6. 6. Source details for this reference are not yet available.
7. 7. Source details for this reference are not yet available.
8. 8. Source details for this reference are not yet available.
9. 9. Source details for this reference are not yet available.